Evolving Risk Factors for Mortality, Progression, Myeloid Dysplasia and Survival in Large 2-Decade Single-Centre Autologous Transplant Cohort of Myeloma, Amyloidosis and related Plasma Cell Dyscrasia

Autologous Stem Cell Transplant (ASCT) with High-Dose Melphalan conditioning has been a unchallenged standard for intensive consolidation therapy in younger fitter Multiple Myeloma (MM) since late 1990,& was ratified as increasing PFS& OS, through RCT by various collaborative groups, as well as meta-analysis.However induction regimens have evolved from anthracycline-based infusions (e.g. [C]VAD& DTPACE]), through thal-& now len- alidomide-based IMid regimens (CTD/DTPACE/CRD), alongside advent of proteasome-inhibitors (esp.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research